

Contents

Contents	v
Author biography	vii
1 Introduction	1
References	3
2 Therapy options for advanced NSCLC	5
First-line chemotherapy and anti-angiogenic agents	5
First-line EGFR tyrosine kinase inhibitors	8
ALK inhibitors	17
References	21
3 Resistance to EGFR TKIs	27
Primary resistance to EGFR-TKIs	27
Acquired resistance to EGFR-TKIs	30
References	34
4 Overcoming EGFR-TKI resistance	37
Overcoming resistance with EGFR-targeted agents	38
Overcoming EGFR-TKI resistance by targeting alternate pathways	42
References	46
5 Resistance to crizotinib and therapeutic options	51
Target-dependent mechanisms	52
Non-target-dependent mechanisms	52
Crizotinib beyond progression	53
Second-generation ALK inhibitors	54
Other agents	56
References	57

6	Resistance to anti-angiogenic drugs and therapeutic options	61
	References	66
7	Conclusion	67

Guide to Targeted Therapies: Treatment Resistance in
Lung Cancer

Cappuzzo, F.

2015, VII, 67 p. 14 illus. in color., Softcover

ISBN: 978-3-319-20740-7